
Tyra Biosciences, Inc. (NASDAQ:TYRA – Free Report) – Equities researchers at HC Wainwright lowered their FY2026 earnings estimates for shares of Tyra Biosciences in a report issued on Wednesday, November 11th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($2.64) for the year, down from their previous estimate of ($2.60). HC Wainwright has a “Buy” rating and a $27.00 price target on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($2.77) per share. HC Wainwright also issued estimates for Tyra Biosciences’ Q4 2026 earnings at ($0.59) EPS, Q1 2027 earnings at ($0.59) EPS, Q2 2027 earnings at ($0.61) EPS, Q3 2027 earnings at ($0.61) EPS, Q4 2027 earnings at ($0.62) EPS and FY2027 earnings at ($2.44) EPS.
Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.07).
Read Our Latest Stock Report on TYRA
Tyra Biosciences Trading Up 1.3%
Tyra Biosciences stock opened at $20.02 on Friday. The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of -7.58 and a beta of 0.65. The firm’s fifty day moving average price is $21.75 and its two-hundred day moving average price is $29.38. Tyra Biosciences has a 1-year low of $14.84 and a 1-year high of $40.65.
Hedge Funds Weigh In On Tyra Biosciences
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Bank of America Corp DE purchased a new position in shares of Tyra Biosciences in the 2nd quarter worth about $11,170,000. Walleye Capital LLC purchased a new stake in Tyra Biosciences during the second quarter worth about $11,112,000. 5AM Venture Management LLC purchased a new stake in Tyra Biosciences during the second quarter worth about $32,875,778. The Manufacturers Life Insurance Company purchased a new stake in Tyra Biosciences during the second quarter worth about $1,416,000. Finally, Squarepoint Ops LLC raised its position in Tyra Biosciences by 211.3% in the second quarter. Squarepoint Ops LLC now owns 63,805 shares of the company’s stock worth $2,038,000 after acquiring an additional 43,311 shares during the period. Hedge funds and other institutional investors own 84.14% of the company’s stock.
Key Headlines Impacting Tyra Biosciences
These are some of the TYRA headlines that stood out recently:
- Positive Sentiment: HC Wainwright kept its Buy rating and $27 price target, while a separate report described analysts as bullish on TYRA. The target suggests potential upside from the recently cited $20.02 price, though it is not a guarantee. Analysts Are Bullish on Top Healthcare Stocks: Claritev (CTEV), Tyra Bioscience (TYRA)
- Neutral Sentiment: Certain restricted stock units are covered by a lock-up agreement ending November 13. The expiry could allow shares to be sold, but the report does not indicate that holders plan to sell. Restricted Stock Unit Lock-Up Agreement
- Negative Sentiment: HC Wainwright lowered most of its 2027 quarterly and full-year EPS forecasts, including FY2027 to a loss of $2.44 per share from $2.27. Its FY2026 loss estimate also edged lower to $2.64 from $2.60, although the Q4 2026 forecast improved. These revisions signal expectations for greater near-term losses despite the continued Buy rating. HC Wainwright Estimate Changes
Tyra Biosciences Company Profile
Tyra Biosciences, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined diseases. Its research focuses on small-molecule therapies that target the fibroblast growth factor receptor (FGFR) family and related pathways, using a drug-discovery approach designed to address resistance and selectivity challenges. The company’s pipeline includes TYRA-300, a selective FGFR3 inhibitor being studied for conditions including achondroplasia and urothelial cancer, and TYRA-200, an FGFR inhibitor being developed for certain cancers.
Recommended Stories
- Five stocks we like better than Tyra Biosciences
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
- 3 GARP Plays That Could Offer a Better Balance as Markets Turn Volatile
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
